查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1573011

血漿衍生性商品市場：按產品類型、應用、最終用戶、來源分類 - 2025-2030 年全球預測

Blood Plasma Derivatives Market by Product Type (Albumin, Coagulation Factors, Immunoglobulins), Application (Diagnostics, Research, Therapeutic Use), End User, Source - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年血漿衍生性商品市值為4.8324億美元，預計2024年將達5.2383億美元，複合年成長率為9.65%，2030年將達到9.2133億美元。

血漿衍生物是指源自人類血漿的治療產品，例如免疫球蛋白、凝血因子和白蛋白，用於治療多種疾病。這些衍生物的需求源自於它們在治療免疫力缺乏疾病、血友病、自體免疫疾病等方面的重要作用。最終用途範圍主要包括醫院、診所和研究機構，此類療法對於挽救生命的干涉措施至關重要。該市場受到血漿分餾技術進步、政府改善醫療基礎設施的舉措以及研究機構和製藥公司之間合作加強等因素的顯著影響。人口老化和慢性病盛行率上升將進一步加速市場成長。然而，嚴格的監管政策和高昂的生產成本帶來了重大挑戰。此外，對血漿捐贈過程的道德擔憂和輸血傳播感染疾病的潛在風險正在阻礙市場擴張。然而，基因研究和生物技術的進步為開發更有效的重組血漿衍生產品提供了機會。專注於改善血漿採集流程和簡化供應鏈可以緩解一些限制。合成生物學的創新可以為更永續和更道德的生產方法鋪平道路，並減少對人類捐贈者的依賴。投資研發夥伴關係來開拓這些領域，確保生產精簡且合規，並將我們的地理覆蓋範圍擴展到醫療保健支出激增的新興市場。此外，加強患者和醫療保健提供者對血漿衍生產品益處的教育可能會提高市場接受度和使用率。總體而言，隨著潛在的技術創新為低成本和道德上合理的替代方案鋪平了道路，市場有望成長。

主要市場統計
基準年[2023] 4.8324 億美元
預測年份 [2024] 52383萬美元
預測年份 [2030] 9.2133億美元
複合年成長率（%） 9.65%

市場動態：快速發展的血漿衍生性商品市場的關鍵市場洞察

供需的動態交互作用正在改變血漿衍生性商品市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 慢性病的流行推動了全球對血漿衍生物的需求
    • 增加對醫療基礎設施和先進血漿採集技術的投資
    • 政府支持血漿衍生物研發的舉措和利多政策
    • 提高患者和醫療保健專業人員對血漿衍生療法的認知和可及性
  • 市場限制因素
    • 用於衍生性商品製造的收集、儲存和分配血漿的物流複雜性
    • 影響血漿衍生物供應鏈的道德問題與捐贈者招募挑戰
  • 市場機會
    • 擴大血漿衍生療法在腫瘤學和重症加護中的使用
    • 技術進步提高血漿衍生物生產效率
    • 政府在突發公共衛生事件期間促進血漿產品使用的努力
  • 市場挑戰
    • 血漿採集和處理的高成本限制了市場擴張
    • 血漿衍生性商品市場中替代療法和生物技術創新的競爭加劇

波特五力：駕馭血漿衍生性商品市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解血漿衍生性商品市場的外部影響

外部宏觀環境因素對血漿衍生性商品市場的表現動態起著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解血漿衍生性商品市場的競爭格局

對血漿衍生性商品市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣血漿衍生性商品市場供應商的績效評估

FPNV定位矩陣是評估血漿衍生性商品市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪血漿衍生性商品市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對血漿衍生性商品市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病的增加導致全球對血漿衍生物的需求增加
      • 增加對醫療基礎設施和先進血漿採集技術的投資
      • 支持血漿分餾產品研發的政府措施和優惠政策
      • 患者和醫療保健專業人員對血漿衍生療法的認知和可及性正在提高
    • 抑制因素
      • 用於衍生性商品製造的收集、儲存和運輸血漿的物流複雜性
      • 影響血漿衍生物供應鏈的道德問題與捐贈者招募挑戰
    • 機會
      • 擴大血漿衍生療法在腫瘤學和加護治療中的使用
      • 提高血漿分餾產品生產效率的技術進步
      • 政府在突發公共衛生事件期間促進血漿產品使用的努力
    • 任務
      • 血漿採集和處理的高成本限制了市場擴張
      • 由於血漿分餾產品市場的替代療法和生物技術創新，競爭日益激烈
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 血漿衍生性商品市場：依產品類型

  • 白蛋白
  • 凝血因子
    • 因子IX
    • 因子VIII
    • 纖維蛋白原濃縮物
    • 凝血酶原複合物濃縮物 (PCC)
  • 免疫球蛋白
    • 靜脈注射（IVIG）
    • 皮下注射 (SCIG)

第7章 血漿衍生性商品市場：依應用分類

  • 診斷
  • 調查
  • 治療用途
    • 心臟病學
    • 血液腫瘤學
    • 免疫學
    • 感染疾病
    • 神經病學
    • 呼吸系統醫療設備
    • 創傷急救

第8章 血漿衍生性商品市場：依最終用戶分類

  • 學術研究所
  • 血庫
  • 診所
  • 診斷實驗室
  • 醫院

第9章 血漿衍生性商品市場：依來源分類

  • 人類血漿
  • 非人類血漿

第10章美洲血漿衍生性商品市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太血漿衍生性商品市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲/中東/非洲血漿衍生性商品市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C008F

The Blood Plasma Derivatives Market was valued at USD 483.24 million in 2023, expected to reach USD 523.83 million in 2024, and is projected to grow at a CAGR of 9.65%, to USD 921.33 million by 2030.

Blood plasma derivatives refer to therapeutic products originating from human plasma, including immunoglobulins, clotting factors, albumin, and others, used to treat a variety of medical conditions. The necessity of these derivatives stems from their vital role in treating immunodeficiency disorders, hemophilia, and autoimmune diseases, among others, which are on the rise globally due to increased diagnosis and awareness. The end-use scope primarily encompasses hospitals, clinics, and research institutions, where such therapeutics are crucial for life-saving interventions. The market is significantly influenced by factors like technological advancements in plasma fractionation, government initiatives to improve healthcare infrastructure, and increased collaborations between research institutions and pharmaceutical companies. An aging population and higher prevalences of chronic diseases further amplify market growth. However, stringent regulatory policies and the high cost of production pose notable challenges. Furthermore, ethical concerns related to plasma donation processes and potential risks of transfusion-transmitted infections hinder market expansion. Nevertheless, advancements in genetic research and biotechnology present opportunities for development of more efficient and recombinant plasma-derived products. Focusing on improving plasma collection processes and enhancing supply chain efficiency can mitigate some limitations. Innovations in synthetic biology open channels for more sustainable and ethical production methodologies, possibly reducing dependence on human donors. Business growth can be achieved by investing in R&D partnerships to explore these areas, ensuring streamlined and compliant production, and by expanding geographical reach to emerging markets witnessing an upsurge in healthcare spending. Additionally, enhancing patient and healthcare provider education on the benefits of plasma-derived products could foster market acceptance and usage. Overall, the market is poised for growth with potential innovations paving the way for less costly and ethically sound alternatives.

KEY MARKET STATISTICS
Base Year [2023] USD 483.24 million
Estimated Year [2024] USD 523.83 million
Forecast Year [2030] USD 921.33 million
CAGR (%) 9.65%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Blood Plasma Derivatives Market

The Blood Plasma Derivatives Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic diseases driving demand for blood plasma derivatives globally
    • Rising investments in healthcare infrastructure and advanced plasma collection technologies
    • Government initiatives and favorable policies supporting blood plasma derivative research and development
    • Growing awareness and accessibility of plasma-derived therapies among patients and healthcare providers
  • Market Restraints
    • Logistical complexities in the collection, storage, and distribution of blood plasma for derivatives production
    • Ethical concerns and donor recruitment challenges affecting the supply chain of blood plasma derivatives
  • Market Opportunities
    • Expanding use of plasma-derived therapies in oncology and critical care
    • Technological advancements improving production efficiency of plasma derivatives
    • Government initiatives promoting the use of plasma products in public health emergencies
  • Market Challenges
    • High cost of blood plasma collection and processing limiting market expansion
    • Increasing competition from alternative therapies and biotechnology innovations in the plasma derivatives market

Porter's Five Forces: A Strategic Tool for Navigating the Blood Plasma Derivatives Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Blood Plasma Derivatives Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Blood Plasma Derivatives Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Blood Plasma Derivatives Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Blood Plasma Derivatives Market

A detailed market share analysis in the Blood Plasma Derivatives Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Blood Plasma Derivatives Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Blood Plasma Derivatives Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Blood Plasma Derivatives Market

A strategic analysis of the Blood Plasma Derivatives Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Blood Plasma Derivatives Market, highlighting leading vendors and their innovative profiles. These include ADMA Biologics, ARTHREX GmbH, Bio Products Laboratory Ltd, Biotest AG, BPL Holdings, China Biologic Products Holdings, Inc., CSL Behring, Emergent BioSolutions, Grifols, Intas Pharmaceuticals, Kamada Ltd., Kedrion Biopharma, LFB Group, Octapharma, Prothya Biosolutions, RAAS Blood Products, Sanquin, Shanghai RAAS Blood Products Co., Ltd., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Blood Plasma Derivatives Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Albumin, Coagulation Factors, and Immunoglobulins. The Coagulation Factors is further studied across Factor IX, Factor VIII, Fibrinogen Concentrate, and Prothrombin Complex Concentrate (PCC). The Immunoglobulins is further studied across Intravenous (IVIG) and Subcutaneous (SCIG).
  • Based on Application, market is studied across Diagnostics, Research, and Therapeutic Use. The Therapeutic Use is further studied across Cardiology, Hemato-oncology, Immunology, Infectious Diseases, Neurology, Pulmonology, and Trauma Emergencies.
  • Based on End User, market is studied across Academic & Research Institutes, Blood Banks, Clinics, Diagnostic Laboratories, and Hospitals.
  • Based on Source, market is studied across Human Plasma and Non-Human Plasma.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases driving demand for blood plasma derivatives globally
      • 5.1.1.2. Rising investments in healthcare infrastructure and advanced plasma collection technologies
      • 5.1.1.3. Government initiatives and favorable policies supporting blood plasma derivative research and development
      • 5.1.1.4. Growing awareness and accessibility of plasma-derived therapies among patients and healthcare providers
    • 5.1.2. Restraints
      • 5.1.2.1. Logistical complexities in the collection, storage, and distribution of blood plasma for derivatives production
      • 5.1.2.2. Ethical concerns and donor recruitment challenges affecting the supply chain of blood plasma derivatives
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding use of plasma-derived therapies in oncology and critical care
      • 5.1.3.2. Technological advancements improving production efficiency of plasma derivatives
      • 5.1.3.3. Government initiatives promoting the use of plasma products in public health emergencies
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of blood plasma collection and processing limiting market expansion
      • 5.1.4.2. Increasing competition from alternative therapies and biotechnology innovations in the plasma derivatives market
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Blood Plasma Derivatives Market, by Product Type

  • 6.1. Introduction
  • 6.2. Albumin
  • 6.3. Coagulation Factors
    • 6.3.1. Factor IX
    • 6.3.2. Factor VIII
    • 6.3.3. Fibrinogen Concentrate
    • 6.3.4. Prothrombin Complex Concentrate (PCC)
  • 6.4. Immunoglobulins
    • 6.4.1. Intravenous (IVIG)
    • 6.4.2. Subcutaneous (SCIG)

7. Blood Plasma Derivatives Market, by Application

  • 7.1. Introduction
  • 7.2. Diagnostics
  • 7.3. Research
  • 7.4. Therapeutic Use
    • 7.4.1. Cardiology
    • 7.4.2. Hemato-oncology
    • 7.4.3. Immunology
    • 7.4.4. Infectious Diseases
    • 7.4.5. Neurology
    • 7.4.6. Pulmonology
    • 7.4.7. Trauma Emergencies

8. Blood Plasma Derivatives Market, by End User

  • 8.1. Introduction
  • 8.2. Academic & Research Institutes
  • 8.3. Blood Banks
  • 8.4. Clinics
  • 8.5. Diagnostic Laboratories
  • 8.6. Hospitals

9. Blood Plasma Derivatives Market, by Source

  • 9.1. Introduction
  • 9.2. Human Plasma
  • 9.3. Non-Human Plasma

10. Americas Blood Plasma Derivatives Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Blood Plasma Derivatives Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Blood Plasma Derivatives Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ADMA Biologics
  • 2. ARTHREX GmbH
  • 3. Bio Products Laboratory Ltd
  • 4. Biotest AG
  • 5. BPL Holdings
  • 6. China Biologic Products Holdings, Inc.
  • 7. CSL Behring
  • 8. Emergent BioSolutions
  • 9. Grifols
  • 10. Intas Pharmaceuticals
  • 11. Kamada Ltd.
  • 12. Kedrion Biopharma
  • 13. LFB Group
  • 14. Octapharma
  • 15. Prothya Biosolutions
  • 16. RAAS Blood Products
  • 17. Sanquin
  • 18. Shanghai RAAS Blood Products Co., Ltd.
  • 19. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • 20. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. BLOOD PLASMA DERIVATIVES MARKET RESEARCH PROCESS
  • FIGURE 2. BLOOD PLASMA DERIVATIVES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. BLOOD PLASMA DERIVATIVES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. BLOOD PLASMA DERIVATIVES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BLOOD PLASMA DERIVATIVES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BLOOD PLASMA DERIVATIVES MARKET DYNAMICS
  • TABLE 7. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FIBRINOGEN CONCENTRATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE (PCC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INTRAVENOUS (IVIG), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBCUTANEOUS (SCIG), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMATO-ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TRAUMA EMERGENCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HUMAN PLASMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NON-HUMAN PLASMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 118. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 125. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 132. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 139. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. PHILIPPINES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 146. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. SINGAPORE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 153. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. SOUTH KOREA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 160. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. TAIWAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 167. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. THAILAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 174. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. VIETNAM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 189. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. DENMARK BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 196. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. EGYPT BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 203. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. FINLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 210. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. FRANCE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 216. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 217. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. GERMANY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 224. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. ISRAEL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 231. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. ITALY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 238. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 239. NETHERLANDS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 244. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 245. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 246. NIGERIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 251. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 252. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 253. NORWAY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 258. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 259. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 260. POLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 266. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 267. QATAR BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 272. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 273. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. RUSSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 280. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 281. SAUDI ARABIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 286. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. SOUTH AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 293. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 294. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 295. SPAIN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 300. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 301. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 302. SWEDEN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 307. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 308. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 309. SWITZERLAND BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 314. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 315. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 316. TURKEY BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED ARAB EMIRATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 328. UNITED KINGDOM BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)

TABLE 3